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Abstract
Background: MALT1 belongs to a family of paracaspase and modulates NF-κB signaling pathways through its
scaffolding function and proteolytic activity. MALT1 cleaves protein substrates after a positively charged Arginine
residue. BCL10, a 233 amino acids polypeptide, is identified as one of the MALT1 proteolytic substrates. MALT1
cleaves BCL10 at the C-terminal end of Arg228. A mere 5 amino acids difference between the substrate and the
proteolytic product made it difficult to tell whether the cleavage event took place by using a simple western blot
analysis. Here, BCL10GFP was constructed and utilized to examine the specificity and domain determinants for
MALT1 cleavage in cells.
Methods: Various BCL10GFP constructs were transfected into HEK293T cell with MALT1 construct by using calcium
phosphate-DNA precipitation method. Lysates of transfectants were resolved by SDS/PAGE and analyzed by
western blot analysis.
Results: BCL10GFP was proteolytically processed by MALT1 as BCL10. The integrity of caspase recruitment domain
(CARD) and MALT1-interacting domain on BCL10 were required for MALT1 proteolytic activity. Besides the invariant
P1 cleavage site Arg228, P4 Leu225 played a role in defining BCL10 as a good substrate for MALT1.
Conclusions: We offered a way of monitoring the catalytic activity of MALT1 in HEK293T cells using BCL10GFP as a
substrate. BCL10GFP can be utilized as a convenient tool for studying the determinants for efficient MALT1
cleavage in HEK293T cells
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Background
Human MALT1 (Mucosa-associated lymphoid tissue 1)
contains 824 amino acid residues and an N-terminal
death domain (DD), two immunoglobulin-like (Ig-like)
domains, followed by a C-terminal caspase-like-domain
(CLD) [1,2] and a third Ig-like domain [3]. MALT1, to-
gether with BCL10, has been shown to couple with dif-
ferent CARMA (CARD containing MAGUK protein)
family protein to assemble into the CBM complex to
transduce NF-κB signaling downstream of multiple
receptors [4-8]. MALT1 links the CBM complex to IKK
activation by the recruitment of TRAF6 [3,9]. Besides its
first-identified scaffolding function, the catalytic activity
of MALT1 and the biological consequences resulting
from its proteolytic activation have been topics of great
interest. It has long been known that MALT1 constructs
with mutations in the predicted active site showed a sig-
nificant reduction in their capacity to activate NF-κB
[2,10]. BCL10 was found to be a proteolytic substrate of
MALT1 [11]. However, proteolytic processing of BCL10
is associated with the fibronectin adhesion and not
required for NF-κB activation [11]. It was not until 2008
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that a mechanistic connection between MALT1 protease
activity and NF-κB activation was demonstrated by
Coornaert et al. [12]. They provided evidences that
NFκB signaling was enhanced from A20 cleavage by
MALT1 [12]. Lately, CYLD [13] and RelB [14] were also
reported to be proteolytic targets of MALT1. In addition,
NIK was shown to be processed by IAP2-MALT1 fusion
oncoprotein [15].
By examining the MALT1 cleavage sites in these sub-
strates, they share a common P2-P1 preference for Ser-
Arg. Unlike caspases, which cleave specific substrate
sequences immediately after Asp residues, MALT1 para-
caspase recognizes a substrate sequence with Arg imme-
diately N-terminal to the cleavage site. Lately, the
structure of human MALT1 paracaspase bonded with a
peptide inhibitor was published [16,17]. Both studies
suggested for Arg invariant at the P1 position and pre-
ference for a hydrophobic residue at P4 position. In this
study, BCL10 was fused at the C-terminus with green
fluorescence protein, generating BCL10GFP fusion pro-
tein, to study the determinants required for MALT1
cleavage in HEK293T cells.
Methods
Plasmids and antibodies
EST clone IMAGE:703916, containing the ORF of BCL10
gene was purchased form Invitrogen (Carlsbad, CA) and
utilized as template for construction of all the BCL10-
derived expression vectors. Expression vectors pCMV6/
XL5/MALT1 (containing full length MALT1 cDNA)
and pCMV6/XL5/IAP2 (Containing full length IAP2
cDNA) were purchased from ORIGENE Technologies
Inc. (Rockville, Maryland). Please see the supplementary
for detailed construction information for all BCL10,
IAP2-MALT1 and MALT1 constructs. All the con-
structs were confirmed by sequencing analysis.
Mouse anti-BCL10 monoclonal antibody (sc-5273)
and mouse anti-MALT1 antibody (sc-46677) were pur-
chased from Santa Cruz Biotchnology (Santa Cruz, CA).
Anti-GAPDH antibody (H86504M) was purchased from
Biodesign international (Saco, ME). Rabbit polyclonal
antibody against GFP expressed in E. coli was also gener-
ated for detection of green fluorescence protein. Horse
radish peroxidase-linked donkey anti-rabbit IgG and
sheep anti-mouse IgG were purchased from Amersham
Biosciences.
Cell Culture and Transfection
HEK293T cells were cultured in DMEM containing 10%
(vol/vol) FBS, 50 units/ml penicillin, 50 μg/ml strepto-
mycin, 1.25 μg/ml fungizone (all from GIBCO, Invitro-
gen, Carlsbad, CA) at 37°C in a 5% CO2 incubator.
Transfection was performed by the calcium phosphate-
DNA precipitation method.
Western Blot Analysis
Cells were rinsed with PBS and lysed with RIPA buffer
(150 mM NaCl, 50 mM Tris pH7.5,1% NP40, 0.1%
SDS, 1mM EDTA, 1mM PMSF, 1μg/ml aprotinin, leu-
peptin, pepstatin, 1mM Na3VO4, 1mM NaF). Dena-
tured protein were separated on SDS/polyacrylamide
gels, transferred to Hybond-P membranes (Amersham
Biosciences), and subjected to immunoblotting with
antibodies indicated.
Immunoprecipitation and CIAP Treatment
Cells were rinsed with PBS and lysed with modified
RIPA buffer (150 mM NaCl, 50 mM Tris pH7.5, 1%
NP40, 0.25% Sodium deoxycholate, 1mM EDTA, 1mM
PMSF, 1mg/ml aprotinin, leupeptin, pepstatin, 1mM
Na3VO4, 1mM NaF). 1 mg total cellular protein were
incubated with 5 μl mouse anti-BCL10 antibody
(sc-5273, Santa Crutz Biotchnology) for 16 hr at 4°C.
50μl protein A beads were then added. The whole mix-
tures were incubated at 4°C for 4 hr. Protein A beads
were spun down, washed twice with RIPA buffer and
subjected to Calf Intestine Alkaline Phosphatase (CIAP)
(New England Biolab.) treatment as suggested by the
manufacturer’s protocol.
Protein expression and purification
pET21aBCL10-His and pET21aBCL10-His mutants were
transformed into BL21(DE3) E. coli cells. Protein exp-
ression was induced with 1 mM IPTG (isopropyl β-D-
thiogalactopyranoside) for 4 hr at 37°C. E. coli cells were
lysed in lysis buffer (50 mM NaH2PO4 pH 8.0, 300 mM
NaCl, 10 mM imidazole, 8 M urea), sonicated. The
lysates were centrifuged at 13K rpm (KUBOTA 1920)
for 10 min at 4°C. The soluble fraction was applied to
Ni2+ NTA agarose (Qiagen). Purification was performed
as the manufacture’s instruction. The protein was eluted
with 250 mM imidazole.
pET21a-MALT1-His or pET21a-MALT1C464A-His
was transformed into Arctic-ExpressTM RIL compent
E. coli cells. Protein expression was induced with 1 mM
IPTG (isopropyl β-D-thiogalactopyranoside) for 48 hr at
8°C. E. coli cells were suspended in buffer (50 mM
NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole) and
lysed by 700 psi french press (Thermo IEC FRENCH
press laboratory with mini pressure cell, 120VAC, 60Hz).
The lysates were centrifuged at 13K rpm (KUBOTA 1920)
for 10 min at 4°C. The soluble fraction was applied to Ni2+
NTA agarose (Qiagen). The protein was purified according
to the manufacture’s instruction and eluted with 250 mM
imidazole.
All the purified proteins were dialyzed against PBS and
stored at -70°C freezer in the presence of 20% glycerol.
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In vitro cleavage assay of purified MALT1
50 ng purified BCL10 or mutant BCL10 proteins were
incubated with 1 μg or 2 μg purified full length MALT1
or catalytic-inactive mutant MALT1C464A respectively
for 4 hr at 30°C in 50 mM MES (pH 6.8), 150 mM NaCl,
10% sucrose, 0.1% CHAPS, 10 mM DTT, and 1 M am-
monium citrate. The reaction was subsequently analyzed
by SDS/PAGE, followed by Western blotting with an
anti-BCL10 antibody or with an anti-MALT1 antibody.
Blots were scanned using UVP Biospectrum AC imaging
system. The percentage of BCL10 processed was defined
as the signal of cleaved product divided by the sum of
signal of full-length protein and the cleaved product.
Results
BCL10GFP was proteolytically processed by MALT1
as BCL10
BCL10 was phosphorylated intracellularly and presented as
multiple slowly-migrating forms in the SDS/polyacrylamide
gel (Figure 1A, lane 1; Figure 1B, lane 1). MALT1-induced
cleavage products were difficult to be detected as the mi-



















Figure 1 Proteolytic cleavage of BCL10GFP by MALT1. (A) Lysates of HEK293T cells transfected with BCL10 or BCL10GFP in the absence (-) or
the presence (+) of MALT1 as indicated were immunoprecipitated using anti-BCL10 antibody and treated with or without calf intestine alkaline
phosphatase (CIAP), and analyzed by Western blotting with anti-BCL10 antibody. filled arrow: full length BCL10; unfilled arrow: truncated BCL10
(B) 2×105 HEK293T cells were transfected with 0.25 μg of pRc/CMVBCL10, pRc/CMVBCL10GFP, or pRc/CMVGFP and 2 μg of pCMV6/XL5 or
pCMV6/XL5/MALT1. Western blot analysis of total cell lysates was carried out using anti-BCL10, anti-GFP and anti-MALT1antibodies. B: BCL10; P-B:
phosporylated BCL10; BG: BCL10GFP; P-BG: Phosphorylated BCL10GFP.
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MALT1 was not obviously changed (Figure 1A, lane 3;
Figure 1B, lane 2). Phosphatase treatment converted mul-
tiple forms to a single unmodified BCL10 (Figure 1A,
lane 2) from lysates of cells with BCL10 overexpression.
Whereas in cells co-transfected with MALT1, phosphatase
treatment revealed the apparent emergence of truncated
BCL10 under the unmodified BCL10 (Figure 1A, lane 4).
Without phosphatase treatment, the MALT1-mediated
cleavage event on BCL10 could not be easily identified
using a simple western blot analysis.
MALT1-mediated cleavage occurs at a single site 5
amino acid from the carboxy-terminal end of BCL10
[11]. By fusion of 25 kdalton green fluorescence protein
(GFP) at the carboxy end of BCL10, the cleavage event
could be easily monitored by the appearance of trun-
cated BCL10 and a form with 5 amino acids from
BCL10 fused at the N-terminus of GFP. BCL10GFP, like
BCL10, was hyperphosphorylated intracellularly and pre-
sented as multiple forms near 55 kdalton (Figure 1A,
lane 5; Figure 1B, lane 3). In addition to these hyperpho-
sphorylated forms of BCL10GFP, multiple forms mig-
rating between 33 and 40 kdalton were consistently
observed in lysates from cells expressing both BCL10GFP
and MALT1 (Figure 1A, lane 7; Figure 1B, lane 4). As
shown in Figure 1A (lanes 7, 8), phosphatase treatment
converted MALT1-induced forms to a form as the trun-
cated BCL10 migrating below the endogenous non-
modified BCL10. A form with molecular weights near 25
kdalton, where GFP was expected to appear (Figure 1B,
middle panel, lanes 5-6), was also detected using anti GFP
antibodies (Figure 1B, middle panel, lane 4) in lysates
from cells cotransfected with BCL10GFP and MALT1
but not from cells with expression of BCL10GFP only
(Figure 1B,middle panel, lane 3). These results indicated
that BCL10GFP could be proteolytically processed by
MALT1 as BCL10. The appearance of a form near 25
kdalton using anti-GFP antibody and multiple forms be-
tween 33 and 40 kdalton using anti-BCL10 antibody
could be utilized as indicators for the occurrence of a
MALT1-mediated cleavage event.
Both the Ig-like and caspase-like-domains of MALT1 were
required for mediating BCL10GFP cleavage
Several deletion mutants (Figure 2A) of MALT1 were gener-
ated to map the domain(s) critical for BCL10GFP cleavage.
While N-terminal DD domain (MALT1 127-824, Figure 2B,
lanes 3, 10) was not essential for MALT1-mediated proteo-
lytic event, deletion of the DD and two Ig-like domains
(MALT1 306-824) abolished the effect (Figure 2B, lane 11).
The proteolytic activity was dependent on an intact caspase-
like-domain, as deletion mutants (MALT1 1-548, MALT1
Δ498-548, MALT1 Δ199-498) showed no significant activity
(Figure 2B, lanes 4, 5, 6). The IAP2-MALT1 fusion protein,
containing the two Ig-like and caspase-like-domains of
MALT1, retained the ability of inducing BCL10GFP cleavage
(Figure 2B, lane 7). Catalytic diads (His415 and Cys464) of
MALT1 paracaspase were identified as critical residues en-
gaging the proteolytic reaction (Figure 2C, lanes 4 and 5) as
previously reported [11,12].
MALT1-induced proteolytic cleavage of BCL10GFP was
dependent upon the integrity of CARD domain and
MALT1 interacting domain on BCL10
Truncation of the N terminus CARD domain (C’BC
L10GFP) or a single mutation (BCL10L41RGFP) in the
CARD domain of BCL10 abolished its phosphorylation
(Additional file 1: Figure S1). In addition to the expected
size of expression, several truncated forms were consist-
ently observed in lysates of cells with expression of these
two mutants alone (Figure 3A, lanes 7, 9). The identity
of these truncated products remained to be determined.
The expression of MALT1 did not alter the expression
pattern of these mutants (Figure 3A, lanes 7, 8, 9, 10).
These findings suggested that CARD domain was required
for phosphorylation and MALT1-induced proteolytic
cleavage on BCL10GFP. It has been shown that the amino
acid residues 106-120 of BCL10 interact with MALT1
[2,10]. Deletion of aa 107-119 (BCL10Δ107-119GFP)
diminished its ability of being processed by a MALT1-
induced event (Figure 3A. lanes 3, 4), indicating that the
interaction of BCL10 with MALT1 was critical for the
proteolytic reaction.
A single amino acid deletion or mutation at Leu225 on
BCL10 greatly affected its ability of being cleaved
by MALT1
Serial deletion mutants (Figure 3B) or mutants with point-
mutation were generated to investigate the contribution
of amino acid residues near the P1 position – Arg228.
MALT1-induced truncated forms could be observed in the
lysates of cells with BCL10C1GFP expression (Figure 3B).
BCL10C2GFP, BCL10C3GFP, and BCL10C4GFP, retaining
the invariant Arg228 in the P1 position, were not good sub-
strates for MALT1 (Figure 3B). In fact, a single amino acid
deletion at Leu225 of BCL10 (BCL10Δ225LGFP) dim-
inished greatly the MALT1-induced proteolytic event
(Figure 3A, lanes 5, 6). A mutation at Arg226 to Glycine
(BCL10R226GGFP), a mutation at Ser227 to Ala (BCL10S2
27AGFP), and a mutation at Ser231 to Ala (BCL10S231
GGFP) had no effect on their abilities of being processed by
MALT1 (Figure 3C, lanes 5-10). Mutants with mutation at
the invariant P1 Arg228 including BCL10R228DGFP,
BCL10R228FGFP, BCL10R228GGFP, BCL10R228KGFP, and
BCL10R228I GFP (Figure 3D), lost their abilities of being
processed. For P4 Leu225, mutants such as BCL10L225
AGFP, BCL10L225GGFP, BCL10L225DGFP, BCL10L225
EGFP, BCL10L225QGFP, BCL10L225KGFP, and BCL10L
225TGFP were not processed by MALT1 (data not shown).
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However, BCL10L225RGFP was proteolytically processed by
MALT1 as BCL10GFP (Figure 3E). Alkaline phosphatase
treatment of lysates from cells transfected with BCL10
L225R and MALT1 revealed the appearance of a truncated
BCL10 with faster migrating mobility than MALT1-
processed BCL10 (Figure 3E, right panel, lanes 4 and 6).
In vitro cleavage assays using purified BCL10 and
MALT1 in the presence of kosmotropic salts were also
performed to verify what were observed in vivo. As shown
in Figure 4, albeit at lower efficiency, BCL10L225R was
processed by MALT1. Different from what was shown
in vivo (Figure 3A), BCL10L41R and BCL10Δ107-119
could be processed by MALT1 in vitro in the presence of
kosmotropic salts (Figure 4).
Discussion
BCL10, a binding partner of MALT1, is an identified
MALT1 substrate [11]. BCL10 is a 233 amino acids poly-
peptide. Cleavage of BCL10 by MALT1 occurs at the
C-terminal end of Arg228. Overexpression of BCL10
Figure 2 Mapping domains on MALT1 required for inducing the cleavage of BCL10GFP. (A) Schematic diagram of the deduced protein
domains in human MALT1 and deletion mutants. The numbers indicate the start and the end of the domains. The predicted catalytic residues
(His 415, Cys464) of the caspase-like domain were marked. (B) (C) Western blot analysis of lysates from cells transfected with various constructs as
indicated using anti-BCL10, anti-MALT1, anti-GFP antibodies. Arrow head indicated the expected expression product of each MALT1 expression
vector. Mouse anti-MALT1 antibody (sc-46677, Santa Cruz) was raised against amino acids 525-824 of MALT1. The poor signal in lanes 4 and 5
(panel B) was due to the inferior recognition by this anti-MALT1 antibody. B: BCL10; BG: BCL10GFP; P-BG: Phosphorylated BCL10GFP.
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induces its hyperphosphorylation. The presence of mul-
tiple hyperphosphorylated forms and a mere 5 amino
acids difference between the substrate and the proteo-
lytic product made it difficult to tell whether the cleav-
age event took place by using a simple western blot
analysis. BCL10 cleavage was once reported to be moni-
tored with a neo-epitope antibody that recognizes the
new C-terminus of BCL10 [18]. In this study, we offered
a way of monitoring cleavage of BCL10 by using
BCL10GFP as substrate for MALT1. As shown in
(See figure on previous page.)
Figure 3 Identification of the determinants on BCL10GFP essential for MALT1-induced cleavage. (A) (B) (C) (D) Western blot analysis of
lysates from cells transfected with various constructs indicated in the absence (-) or the presence (+) of MALT1 using anti-BCL10, anti-MALT1
antibodies. (E) Left: Western blot analysis of lysates from HEK293T cells transfected with BCL10GFP or BCL10L225RGFP in the absence (-) or the
presence (+) of MALT1. Right: Lysates of cells transfected with BCL10, BCL10L225K or BCL10L225R in the absence (-) or the presence (+) of MALT1
were treated with alkaline phosphatase and analyzed by western blot analysis. filled arrow: full length BCL10; unfilled arrow: truncated BCL10;




Figure 4 In vitro cleavage assay of BCL10 and mutants by MALT1. (A) His-tagged BCL10 and BCL10 mutants were expressed in E. coli,
purified and incubated with increasing concentrations of His-tagged MALT1 or MALT1C464A mutant respectively. Samples were resolved by
SDS/PAGE, followed by Western blot analysis using anti-MALT1 (top left) or anti-BCL10 antibody. Data are representative of three separate
experiments. (B) Quantitative analysis of (A). The percentage of BCL10 processed was defined as the signal of cleaved product divided by the
sum of signal of full-length protein and the cleaved product.
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Figure 1, we were able to demonstrate the cleavage of
BCL10GFP fusion protein as BCL10 in cells with ectopi-
cal expression of MALT1. When overexpressed, BCL10
GFP formed cytoplasmic filaments as BCL10 did.
Mutation or deletion of the major phosphorylation
sites (Ser 134, Ser 136, Ser 138, Ser 141, Ser 144, Ser 170,
and Ser 171) on BCL10 or BCL10GFP abolished the
appearance of hyperphosphorylated forms as well (data
not shown). All the data indicated that the fusion of GFP
tag on BCL10 did not jeopardize its ability of being
phosphorylated or as a substrate for MALT1. Hence,
BCL10GFP can be utilized as a convenient tool for study-
ing the determinants for efficient MALT1 cleavage in
HEK293T cells.
BCL10 binds directly and constitutively to the DD and
the first two Ig-like regions of MALT1 [2,3,10,19]. Con-
sistent with others, deletion of the DD of MALT1
(MALT1 127-824) had little influence on its protease ac-
tivity. Deletion of both DD and Ig-like domains (MALT1
306-824), abolishing the interaction with BCL10, greatly
affected its proteolytic activity on BCL10GFP (Figure 2B).
However, DD and the first two Ig-like domains of MALT1
are not required for activity in vitro using peptide sub-
strates such as the BCL10-based substrate Ac-LRSR-amc
[17,20]. IAP2-MALT1 fusion oncoprotein induces cleav-
age of NIK [15]. NIK is recruited to the IAP2 moiety of
IAP2-MALT1 fusion protein and is cleaved by the MALT1
paracaspse domain [15]. Cleavage of NIK is not observed
in cells expressing activated MALT1 [15]. Therefore, for
cleavage of natural protein substrates as opposed to pep-
tide substrates, interactions between protease and sub-
strate are critical.
Based on sequence alignment with caspases, metacas-
pases, miscellaneous eukaryotic and bacterial cysteine pro-
teases, His415 and Cys464 of MALT1 were identified as
the possible catalytic diad [2]. Indeed, mutation of these
two residues abolished its catalytic activity (Figure 2C).
MALT1 1-548 failed to process BCL10GFP. In this con-
text, an extension of catalytic active site into a region
C-terminal to the cited caspase-like-domain is suggested.
These results coincided with two recent studies indicating
that deletion of domains C-terminal to the caspase-like
domain jeopardized its stability [16,17]. In fact, the
caspase-like domain and the following Ig domain are
shown to appear as a single folding unit [16].
The expression of MALT1 alone is insufficient to induce
proteolytic activation. The activation of MALT1 can be
achieved by overexpression of BCL10 [11,12] in cells.
Homotypic interactions between the CARD domain
results in the oligomerization of BCL10, which in turn
mediates the oligomerization and activation of MALT1.
Deletion (C’BCL10GFP) or mutation (BCL10L41RGFP) of
the CARD domain failed to activate MALT1. Hence, both
mutants were not processed in vivo due to the failure of
generating a functional MALT1 paracaspase. BCL10L41R
was still a substrate for activated MALT1. In vitro, kos-
motropic salts mediated the oligomerization of MALT1
and the activation of its catalytic activity, bypassing
BCL10-mediated oligomerization. Hence, BCL10L41R
was processed by MALT1 in vitro in the presence of
kosmotropic salts.
Unlike the related metacaspases, which accept both Lys
and Arg as a P1 residue [21], the analysis of crystal struc-
ture of MALT1 paracaspase region suggests a degree of
conserved substrate specificity with Arg invariant at the
P1 position [16,17]. The positively charged P1 residue Arg
is coordinated by three highly conserved acidic residues in
the S1 pocket. The carboxylate side chain of each of the
three acidic residues accepts a pair of charge-stabilized
hydrogen bonds from the guanidinium group of P1-Arg.
Our results that a mutation of Arg228 to Asp, Phe, Gly,
Lys, or Ile of BCL10GFP abolished its activity of being
processed by MALT1 are consistent with these findings. A
mutation of P2-Ser227 to Ala227 on BCL10GFP had no
effect on its ability of being a substrate for MALT1, coin-
cided with the finding that P2 position was moderately se-
lective for amino acids with small side chains due to a
restricted S2 pocket [16]. A mutation to Gly at the P3
Arg226 (BCL10R226GGFP) retained its ability of being
processed by MALT1. The result was in agreement with
the notion that there was small contribution of P3 residue
for substrate recognition.
The shallow, hydrophobic S4 pocket of MALT1 is open to
accommodate hydrophobic residues. Hence, preference for a
hydrophobic residue at P4 position is suggested [16,17].
While the manuscript was in preparation, Hachmann et al.
reported the optimal cleavage sequence for MALT1 using
positional-scanning peptidyl substrate libraries [20]. Leucine
was shown to be strongly favored in the P4 position. The
observation that serial deletion mutants BCL10C2GFP,
BCL10C3GFP and BCL10C4GFP, though retaining the P1-
Arg228, lost their abilities of being MALT1 substrates might
simply be due to the loss of a hydrophobic P4 residue.
BCL10Δ225LGFP utilizing Pro224 as the cryptic P4 residue
lost its ability of being processed by MALT1. A serial of
BCL10GFP mutants (L225A, L225G, L225D, L225E, L225Q,
L225T, L225R, L225K) with mutation at the P4-Leu225 resi-
due were tested. All but one (BCL10L225RGFP) lost their
abilities of being substrates for MALT1. The observation that
BCL10L225R could be processed by MALT1 using in vivo
and in vitro assay seemed to be conflicted with the notion
that polar residues in the P4 position were not tolerated [20].
However, the truncated products from BCL10L225R pro-
cessed by MALT1 migrated faster than those from wild type
BCL10 processed by MALT1 (Figure 3E). Mutation at
Phe222 to His, Ser, or Glu on BCL10L225R abolished the
cleavage (data not shown). Therefore, a cryptic cleavage site
at the carboxyl-end of L225R was highly suspected.
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Using BCL10, the natural substrate of MALT1, as a tool,
the major determinants for MALT1 cleavage are consist-
ent with what were found in vitro with peptidyl substrates.
Since it was not possible to screen for preferences in P1’
positions (C-terminal to the scissile bond) using peptidyl
substrate, our system utilizing BCL10GFP can be a good
tool to address the issue.
Conclusions
We offered a way of monitoring the catalytic activity of
MALT1 in HEK293Tcells using BCL10GFP as a substrate.
BCL10GFP can be utilized as a convenient tool for study-
ing the determinants for efficient MALT1 cleavage in
HEK293T cells.
Additional file
Additional file 1: Figure S1. Mutation (BCL10L41RGFP) or deletion
(C’BCL10GFP) of CARD on BCL10 abolished its ability of being
phosphorylated and processed by MALT1.
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